Cigna Corporation Announces Pricing of $20 Billion of Senior Notes
BLOOMFIELD, Conn., 06 September, 2018 - Cigna Corporation (NYSE: CI) (“Cigna”) today announced that Halfmoon Parent, Inc. (the “Issuer”), a direct wholly owned subsidiary of Cigna, priced an offering (the “Offering”) of $1,000,000,000 aggregate principal amount of Senior Floating Rate Notes due 2020 with an interest rate equal to the three-month LIBOR plus 0.35% per annum, $1,750,000,000 aggregate principal amount of 3.200% Senior Notes due 2020, $1,000,000,000 aggregate principal amount of Senior Floating Rate Notes due 2021 with an interest rate equal to the three-month LIBOR plus 0.65% per annum, $1,250,000,000 aggregate principal amount of 3.400% Senior Notes due 2021, $700,000,000 aggregate principal amount of Senior Floating Rate Notes due 2023 with an interest rate equal to the three-month LIBOR plus 0.89% per annum, $3,100,000,000 aggregate principal amount of 3.750% Senior Notes due 2023, $2,200,000,000 aggregate principal amount of 4.125% Senior Notes due 2025, $3,800,000,000 aggregate principal amount of 4.375% Senior Notes due 2028, $2,200,000,000 aggregate principal amount of 4.800% Senior Notes due 2038, and $3,000,000,000 aggregate principal amount of 4.900% Senior Notes due 2048 (collectively, the “Notes”).
The Offering is expected to close on September 17, 2018, subject to customary closing conditions. All of the Notes, except the 4.900% Senior Notes due 2048, are subject to a special mandatory redemption if the pending acquisition of Express Scripts Holding Company (as more fully set forth in the definitive documentation related to the Offering) (the “Acquisition”) does not occur before September 4, 2019 or if the Issuer notifies the trustee that it will not pursue the consummation of the Acquisition. The Issuer intends to use the proceeds of the Notes, together with cash on hand and the proceeds of borrowings under certain credit facilities and/or issuances of commercial paper, to pay, in part, the cash portion of the consideration for the Acquisition, to repay certain indebtedness of Express Scripts Holding Company and its subsidiaries and/or to pay fees and expenses in connection with the foregoing. The Issuer intends to use the proceeds of the Notes not applied as described in the preceding sentence, if any, for general corporate purposes, which may include payment of certain obligations in respect of the special mandatory redemption and payment of interest on the Notes. There can be no assurance that either the issuance and sale of the Notes or the Acquisition will be consummated.
The Notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A and to certain non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The Notes have not been registered under the Securities Act or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws.
This press release does not constitute an offer to sell or a solicitation of an offer to purchase the Notes or any other securities and does not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.
FORWARD LOOKING STATEMENTS
Information included or incorporated by reference in this communication, and information which may be contained in other filings with the Securities and Exchange Commission (the “SEC”) and press releases or other public statements, contains or may contain forward-looking statements. These forward-looking statements include, among other things, statements of plans, objectives, expectations (financial or otherwise) or intentions, including statements concerning the ability to achieve the anticipated benefits of the proposed merger and the related financing, on the expected timeline or at all, the ability to consummate the proposed merger and the related financing, on the anticipated timeline or at all, and other statements regarding the parties’ future beliefs, expectations, plans, intentions, financial condition or performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.
Forward-looking statements, including as they relate to Express Scripts or Cigna, the management of either such company, the transaction or any expected benefits of the transaction, involve risks and uncertainties. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Express Scripts and Cigna do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the risks associated with the following:
- the inability of Express Scripts and Cigna to obtain regulatory approvals required for the merger or the requirement to accept conditions that could reduce the anticipated benefits of the merger as a condition to obtaining regulatory approvals;
- the possibility that the anticipated benefits from the merger (including anticipated synergies) cannot be realized in full, or at all or may take longer to realize than expected;
- a longer time than anticipated to consummate the proposed merger;
- problems regarding the successful integration of the businesses of Express Scripts and Cigna;
- unexpected costs regarding the proposed merger;
- diversion of management’s attention from ongoing business operations and opportunities;
- potential litigation associated with the proposed merger;
- the ability to retain key personnel;
- the availability of financing;
- effects on the businesses as a result of uncertainty surrounding the proposed merger;
- the ability of the combined company to achieve financial, strategic and operational plans and initiatives;
- the ability of the combined company to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers;
- the impact of modifications to the combined company’s operations and processes;
- the ability of the combined company to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions;
- the substantial level of government regulation over the combined company’s business and the potential effects of new laws or regulations or changes in existing laws or regulations;
- the outcome of litigation relating to the businesses of Express Scripts and Cigna, regulatory audits, investigations, actions and/or guaranty fund assessments;
- uncertainties surrounding participation in government-sponsored programs such as Medicare;
- the effectiveness and security of the combined company’s information technology and other business systems;
- unfavorable industry, economic or political conditions, including foreign currency movements;
- acts of war, terrorism, natural disasters or pandemics; and
- the industry may be subject to future risks that are described in SEC reports filed by Express Scripts and Cigna.
You should carefully consider these and other relevant factors, including those risk factors in this communication and other risks and uncertainties that affect the businesses of Express Scripts and Cigna described in their respective filings with the SEC, when reviewing any forward-looking statement. These factors are noted for investors as permitted under the Private Securities Litigation Reform Act of 1995. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider the foregoing list, or the risks identified in SEC filings, to be a complete discussion of all potential risks or uncertainties, and should not place undue reliance on forward-looking statements.
IMPORTANT INFORMATION ABOUT THE TRANSACTION AND WHERE TO FIND IT
This communication does not constitute an offer to sell or solicitation of an offer to buy any securities. In connection with the proposed merger with Express Scripts, the newly formed company which will become the holding company following the transaction (“Holdco”) filed with the SEC a registration statement on Form S-4. The registration statement on Form S-4 includes a joint proxy statement of Cigna and Express Scripts that also constitutes a prospectus of Holdco. These materials are not final and may be further amended. The registration statement was declared effective by the SEC on July 16, 2018, and Cigna and Express Scripts commenced mailing the definitive joint proxy statement/prospectus to the respective stockholders of Cigna and Express Scripts on or about July 17, 2018. Cigna and Express Scripts also plan to file other relevant documents with the SEC regarding the proposed transaction. This document is not a substitute for the registration statement or the joint proxy statement/prospectus or any other document which Cigna, Express Scripts or Holdco may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, JOINT PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. You may obtain a free copy of the registration statement on Form S-4 and the definitive joint proxy statement/prospectus and other relevant documents filed by Holdco, Cigna and Express Scripts with the SEC at the SEC’s website at www.sec.gov. Copies of documents filed with the SEC by Cigna will be available free of charge on Cigna’s website at www.Cigna.com or by contacting Cigna’s Investor Relations Department at (215) 761-4198. Copies of documents filed with the SEC by Express Scripts will be available free of charge on Express Scripts’ website at www.express-scripts.com or by contacting Express Scripts’ Investor Relations Department at (314) 810-3115.
NO OFFER OR SOLICITATION
This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities in any jurisdiction pursuant to or in connection with the proposed merger or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
Other articles in News Releases:
- Cigna Demonstrates Commitment to Health of People, Communities and Environment
- Cigna's U.S. Loneliness Index Provides Actionable Insights for Improving Body and Mind Health
- Cigna Ranked First in the Health Care Industry for Supporting Healthy Communities and Families
- Cigna Foundation Supports Social Connectivity through $150,000 Grant to FiftyForward
- Cigna Collaboration Helps Santa Clara County IPA (SCCIPA) Improve Quality and Lower Costs
- Cigna Corporation Announces Appearance at the Goldman Sachs 40th Annual Global Healthcare Conference